CAR-T cell therapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic prostate cancer that no longer responds to hormone therapy.
- Your PSA must be at least 1 ng/mL and rising within the last 6 months.
- You must have tried at least one other advanced treatment like abiraterone or enzalutamide.
- You must be willing to provide a tumor sample for testing.
- You must not have had a prior CAR-T therapy or a treatment targeting STEAP2.
- You must not have active infections, other cancers, or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a type of immune cell treatment (CAR T) made to recognize PSMA, a marker on prostate cancer cells. It’s for advanced prostate cancer and aims to find a safe dose and how well the treatment works.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.